 |
[Apha Biz=(Chicago) Reporter Paul Lee] Daewoong Pharmaceutical announced on the 4th that it has registered three patents related to autoimmune disease treatment in the past six months, accelerating its dominance in the market. Daewoong Pharmaceutical has six patents registered in connection with the treatment of autoimmune diseases.
Immunovant, a global partner of Daewoong Pharmaceutical's subsidiary Hanall Biopharma, released encouraging first-phase clinical data of its second FcRn antibody drug "IMVT-1402" (HL161ANS), which is being developed as a treatment for autoimmune diseases on the 26th of last month (local time).
In clinical first phase, HL161ANS showed a similar or high level of antibody inhibitory effect to batoclimab. Increased LDL-cholesterol and decreased albumin levels were not observed. The industry expects HL161ANS to become the best drug in the family (Best-In-Class) with the best efficacy, safety, and convenience.
Daewoong Pharmaceutical is working on three projects related to autoimmune diseases in different fields at the same time, including the Kainaise inhibitor.
Daewoong Pharmaceutical is exploring candidate materials with the aim of developing oral treatments that can be applied to central nervous system (CNS) autoimmune diseases, and will be released in the first half of 2024.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
